Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties by Anguille, Sébastien et al.
BioMed  Central
Page 1 of 16
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Research
Short-term cultured, interleukin-15 differentiated dendritic cells 
have potent immunostimulatory properties
Sébastien Anguille*1,2, Evelien LJM Smits1, Nathalie Cools1, 
Herman Goossens1, Zwi N Berneman1,2 and Vigor FI Van Tendeloo1,2
Address: 1University of Antwerp - Faculty of Medicine, Vaccine & Infectious Disease Institute (Vaxinfectio), Laboratory of Experimental 
Hematology, Universiteitsplein 1, B-2610 Wilrijk (Antwerp), Belgium and 2Antwerp University Hospital, Center for Cell Therapy & Regenerative 
Medicine (CCRG), Wilrijkstraat 10, B-2650 Edegem (Antwerp), Belgium
Email: Sébastien Anguille* - sebastien.anguille@uza.be; Evelien LJM Smits - evelien.smits@uza.be; Nathalie Cools - nathalie.cools@uza.be; 
Herman Goossens - herman.goossens@uza.be; Zwi N Berneman - zwi.berneman@uza.be; Vigor FI Van Tendeloo - viggo.van.tendeloo@uza.be
* Corresponding author    
Abstract
Background: Optimization of the current dendritic cell (DC) culture protocol in order to promote the
therapeutic efficacy of DC-based immunotherapy is warranted. Alternative differentiation of monocyte-
derived DCs using granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-15 has
been propagated as an attractive strategy in that regard. The applicability of these so-called IL-15 DCs has
not yet been firmly established. We therefore developed a novel pre-clinical approach for the generation
of IL-15 DCs with potent immunostimulatory properties.
Methods: Human CD14+ monocytes were differentiated with GM-CSF and IL-15 into immature DCs.
Monocyte-derived DCs, conventionally differentiated in the presence of GM-CSF and IL-4, served as
control. Subsequent maturation of IL-15 DCs was induced using two clinical grade maturation protocols:
(i) a classic combination of pro-inflammatory cytokines (tumor necrosis factor-α, IL-1β, IL-6, prostaglandin
E2) and (ii)  a Toll-like receptor (TLR)7/8 agonist-based cocktail (R-848, interferon-γ, TNF-α and
prostaglandin E2). In addition, both short-term (2-3 days) and long-term (6-7 days) DC culture protocols
were compared. The different DC populations were characterized with respect to their phenotypic
profile, migratory properties, cytokine production and T cell stimulation capacity.
Results: The use of a TLR7/8 agonist-based cocktail resulted in a more optimal maturation of IL-15 DCs,
as reflected by the higher phenotypic expression of CD83 and costimulatory molecules (CD70, CD80,
CD86). The functional superiority of TLR7/8-activated IL-15 DCs over conventionally matured IL-15 DCs
was evidenced by their (i)  higher migratory potential, (ii)  advantageous cytokine secretion profile
(interferon-γ, IL-12p70) and (iii) superior capacity to stimulate autologous, antigen-specific T cell responses
after passive peptide pulsing. Aside from a less pronounced production of bioactive IL-12p70, short-term
versus  long-term culture of TLR7/8-activated IL-15 DCs resulted in a migratory profile and T cell
stimulation capacity that was in favour of short-term DC culture. In addition, we demonstrate that mRNA
electroporation serves as an efficient antigen loading strategy of IL-15 DCs.
Conclusions: Here we show that short-term cultured and TLR7/8-activated IL-15 DCs fulfill all pre-
clinical prerequisites of immunostimulatory DCs. The results of the present study might pave the way for
the implementation of IL-15 DCs in immunotherapy protocols.
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Background
Since their discovery by Steinman and Cohn in 1973, den-
dritic cells (DCs) have been recognized as the strategic
orchestrators of the innate and adaptive immune system
[1-3]. Although our knowledge of DC biology is still
expanding, several concepts are yet well established [3,4].
Immature DCs are known to be the vigilant sentinels of
the human immune system; they relentlessly screen the
environment for the presence of antigen and are highly
capable of antigen uptake [4,5]. Mature DCs are able to
present the processed antigens via major histocompatibil-
ity complexes (MHC) to T cells after their migration to
secondary lymphoid organs. This process of DC-mediated
migration is regulated by multiple factors, but expression
of the chemokine receptor CCR7 is recognized to play a
pivotal role [6]. In the lymph nodes, three signals are
required for the formation of an optimal immunological
synapse between DCs and T cells and for the induction of
desired T helper type 1 (Th1) immune response: (1) recog-
nition of MHC-presented antigens by T cell receptors, (2)
delivery of costimulatory signals via the CD80/CD86-
CD28 pathway, and (3)  secretion of interleukin (IL)-
12p70 by DCs after CD40/CD40 ligand signalling [5].
Since DCs are key regulators of the human immune sys-
tem, their use under the form of a cellular vaccine is an
attractive strategy for the treatment of cancer and infec-
tious diseases [3]. Since the results of the first clinical DC
vaccine trial were published in 1996 [7], the field of DC-
based immunotherapy has been increasingly translated
into clinical practice, as evidenced by the growing number
of clinical studies. To date, more than 100 trials have been
performed or are currently ongoing to evaluate the effect
of DC vaccines in a wide variety of disease states, with a
main focus on the treatment of cancer [4].
While CD34+ bone marrow progenitor cells and circulat-
ing blood myeloid DCs have been applied as DC precur-
sors in some clinical studies, the vast majority of DCs used
for vaccination purposes are derived from autologous
peripheral blood monocytes [8]. The classic strategy for
the ex vivo generation of monocyte-derived DCs consists
of a two-step culture protocol, in which monocytes are
differentiated towards immature DCs, followed by the
induction of DC maturation. The total in vitro culture
duration lasts one week, 5-6 days for DC differentiation
and 1-2 days for subsequent DC maturation [5,9,10].
However, there is an increasing body of evidence that
mature monocyte-derived DCs can be generated even
after short-term cell culture for 2-3 days [9,11-15]. As
compared to the traditional 7-day approach, rapid expan-
sion of DCs is associated with several advantages; it sim-
plifies the laborious and time-consuming process of DC
manufacturing and it reduces the actual risk of microbial
contamination related to in vitro culture [10,15]. Moreo-
ver, short-term cultured DCs exhibit equal or superior
functional DC characteristics compared to their conven-
tional long-term counterparts [13,14]. Previous work has
already demonstrated the feasibility of short-term culture
of monocyte-derived DCs differentiated in the presence of
granulocyte macrophage colony-stimulating factor (GM-
CSF) and IL-4 (IL-4 DCs) [12-16].
Alternative differentiation of monocyte-derived DCs
using a combination of GM-CSF and IL-15 has recently
gained increasing interest. Interleukin-15 is a pleiotropic
cytokine that plays a pivotal role in the generation of anti-
gen-specific CD8+ T lymphocytes [17-19], the induction
of memory CD8+ T cell immunity [20] and natural killer
(NK) cell activation [21]. Interleukin-15 differentiated
DCs (IL-15 DCs) have been previously described to
exhibit a distinct Langerhans cell(LC)-like phenotype and
to possess unique immunostimulatory properties [22,23].
This was more recently supported by the demonstration
that IL-15 DCs are endowed with a superior capacity to
induce antigen-specific cellular immune responses in an
in vitro melanoma tumor model [24,25]. These promising
results make IL-15 DCs a qualified candidate for applica-
tion in DC-based tumor immunotherapy [4,26].
In addition, the Toll-like receptor (TLR) signal transduc-
tion pathway has recently emerged as an attractive alterna-
tive for the induction of DC maturation [10,27,28]. Toll-
like receptors recognize pathogen-derived signals, such as
microbial constituents (viral or bacterial-derived proteins,
RNA or DNA) [29,30]. Monocyte-derived DCs are known
to express a series of TLRs, either on their cell surface
(TLR2, TLR4) or intracellularly (TLR3, TLR7, TLR8 and
TLR 9) [27]. Recent studies have suggested that DC matu-
ration using TLR3 or TLR7/8 ligands in association with
prostaglandin E2 (PGE2) results in the generation of DCs
that, besides migratory properties, possess the desired
capacity to produce Th1-polarizing cytokines such as IL-
12p70 [31-33]. In the context of cancer immunotherapy,
Th1 polarization is considered conditio sine qua non for the
induction of anti-tumor cytotoxic immune responses.
However, despite the discovery of TLR ligands as powerful
DC maturation agents, a non-TLR ligand-based matura-
tion cocktail is currently regarded as the 'gold standard' for
the induction of DC maturation in clinical trials. This
widely adopted maturation cocktail was first described by
Jonuleit et al. and is composed of the pro-inflammatory
cytokines tumor necrosis factor (TNF)-α, IL-1β, IL-6 and
PGE2 [34]. Prostaglandin E2 is generally believed to be
indispensable for potentiating the migratory potential of
DCs [35,36], but hampered IL-12p70 production is con-
sidered to be its main drawback [37-39].
In view of the consideration that short-term DC culture,
differentiation with IL-15 and TLR-induced maturationJournal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
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are proposed as separate attractive strategies to optimize
the immunogenicity of clinical DC vaccination, we sought
to determine whether an integration of these approaches
is feasible and results in the generation of potent immu-
nostimulatory DCs. We therefore examined the effect of
culture duration on IL-15 DC phenotype and function by
comparing short-term and long-term culture protocols. In
addition, we evaluated the effect of two different matura-
tion procedures on IL-15 DCs, juxtaposing the traditional
pro-inflammatory cytokine combination with a clinical
grade available maturation cocktail that includes a TLR7/
8 ligand (resiquimod; R-848).
Methods
Generation of immature DCs
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from healthy donor buffy coat preparations using a
standard density-gradient centrifugation technique
(Ficoll-Paque™ PLUS, GE Healthcare; Diegem, Belgium).
The freshly isolated PBMC-fraction was instantly used for
immunomagnetic cell selection of monocytes with CD14
microbeads (Miltenyi Biotec; Amsterdam, The Nether-
lands). The CD14-depleted cell fraction, composed of
peripheral blood lymphocytes (PBLs), was immediately
cryopreserved in freezing solution containing 90% fetal
calf serum (Perbio Science; Erembodegem, Belgium)/10%
dimethyl sulfoxide (Sigma-Aldrich; Bornem, Belgium)
and stored at -80°C until use. The positively selected cell
population (mean purity of CD14+ monocytes ± SD: 96.7
± 1.5%), was subsequently used for the in vitro generation
of DCs. For this purpose, monocytes were resuspended in
RPMI 1640 culture medium (BioWhittaker; Verviers, Bel-
gium) supplemented with 2.5% heat-inactivated human
AB serum and seeded in 6-well culture plates (Corning
Life Sciences; Schiphol-Rijk, The Netherlands) at a final
concentration of 1-1.2 × 106/mL. Monocytes were cul-
tured with 800 IU/mL GM-CSF (Gentaur; Brussels, Bel-
gium) and 20 ng/mL IL-4 (Gentaur; Brussels, Belgium) or
200 ng/mL IL-15 (Immunotools; Friesoythe, Germany) in
order to generate immature IL-4 DCs and IL-15 DCs,
respectively (Table 1).
Induction of DC maturation
Two different maturation cocktails were used for the
induction of DC maturation. The conventionally applied
combination of pro-inflammatory cytokines, first
described by Jonuleit et al. [34], was compared with a
TLR7/8 agonist-based maturation cocktail. Table 1 pro-
vides an overview of the composition of the different mat-
uration cocktails used in this study (Table 1). The
resultant mature DCs were harvested 24 hr after addition
of the maturation agents.
Duration of in vitro culture
Short-term versus long-term culture protocols were per-
formed in order to determine the effect of culture duration
on IL-15 DC phenotype and function. Short-term DCs
were cultured for two days and subsequently matured for
another 24 hr. Likewise, the long-term DC culture proto-
col included a six-day period for the generation of imma-
ture DCs followed by one day to obtain complete
maturation.
Flow cytometric immunophenotyping
Immunofluorescent staining of cell surface antigens was
performed using a panel of fluorescein isothiocyanate
Table 1: Differentiation and maturation procedures used in the present study.
Dendritic cell differentiation
IL-4 differentiated dendritic cells (IL-4 DCs)
GM-CSF 800 IU/mL Gentaur, Brussels, Belgium
IL-4 20 ng/mL R&D Systems, Minneapolis, USA
IL-15 differentiated dendritic cells (IL-15 DCs)
GM-CSF 800 IU/mL Gentaur, Brussels, Belgium
IL-15 200 ng/mL Immunotools, Friesoythe, Germany
Dendritic cell maturation
cc-mDC (conventional maturation cocktail, according to Jonuleit et al. [34])
TNF-α 10 ng/mL Biosource, Nivelles, Belgium
IL-1β 10 ng/mL R&D Systems, Minneapolis, USA
IL-6 15 ng/mL Biosource, Nivelles, Belgium
PGE2 1 μg/mL Pfizer, Puurs, Belgium
TLR-mDC (TLR7/8 agonist-based maturation cocktail)
R-848 (Resiquimod) 3 μg/mL Alexis Biochemicals, San Diego, USA
TNF-α 2.5 ng/mL Biosource, Nivelles, Belgium
IFN-γ 5000 IU/mL Immunotools, Friesoythe, Germany
PGE2 1 μg/mL Pfizer, Puurs, BelgiumJournal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
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(FITC)- or phycoerythrin (PE)-conjugated monoclonal
antibodies (mAb): CD1a (FITC, clone HI149), CD14
(FITC, clone MϕP9), CD40 (PE, clone 5C3), CD56 (FITC,
clone NCAM16.2), CD70 (PE, clone Ki-24), CD80 (PE,
clone L307.4), CD83 (PE, clone HB15e), CD86 (FITC,
2331 [FUN-1]), CD207/Langerin (PE, clone DCGM4),
CD209/DC-SIGN (FITC, clone DCN46) and CCR7 (PE,
clone 150503). All monoclonal antibodies were pur-
chased from BD Biosciences (Erembodegem, Belgium),
except for CD83 mAb (Invitrogen; Camarillo, CA, USA),
CD207 mAb (Beckman Coulter; Marseille, France), and
CCR7 mAb (R&D Systems; Minneapolis, MN, USA). Cor-
responding species- and isotype-matched antibodies were
used as controls. Propidium iodide (PI; Sigma-Aldrich)
was included in the analysis to discriminate between via-
ble and dead cells. Data acquisition was performed on a
FACScan™ multiparametric flow cytometer (BD Bio-
sciences).
FITC-dextran endocytosis assay
The mannose receptor-mediated endocytosis of FITC-
labeled dextran particles (MW 40 kDa; Sigma-Aldrich)
was determined by co-incubation of 0.4 × 106 immature
DCs with 100 μg/mL FITC-dextran at 37°C. Parallel exper-
iments were carried out at 4°C to determine the non-spe-
cific FITC-dextran uptake (negative controls). After 60
minutes, internalization of FITC-dextran was stopped by
washing the cells twice with ice-cold phosphate-buffered
saline (PBS; Gibco Invitrogen; Paisley, UK). The endocytic
capacity was subsequently analyzed by flow cytometric
quantitation of the specific FITC fluorescence signal inten-
sity.
Transwell™ chemotaxis assay
The migratory potential of IL-15 DCs was determined by
a chemotaxis assay using 24-well culture plates carrying
polycarbonate membrane-coated Transwell™ permeable
inserts (5 μm pore size; Costar). First, the lower plate
chambers were filled with 600 μL DC culture medium per
well. The CCR7 ligand 6Ckine/CCL21 (R&D Systems)
served as chemotactic agent and was added to the lower
well at an optimal concentration of 100 ng/mL. Next, DCs
(1.0 × 105 cells) were seeded on each Transwell™ insert in
a total volume of 100 μL DC culture medium and allowed
to migrate to the lower compartments for 180 min in a
humidified 37°C/5% CO2  incubator (chemokine-driven
migration). Parallel control experiments were conducted
in the absence of CCL21 to assess the spontaneous cell
migration (negative control) or by transferring all cells (1.0
× 105) to the lower well in order to determine the maxi-
mum possible DC yield (positive control). Thirty minutes
prior to harvest, 5 mM EDTA (Merck; Darmstadt, Ger-
many) was added to the lower compartments to detach
the adherent, transmigrated cells. Finally, the cells from
each lower well were collected, centrifuged and concen-
trated to a final sample volume of 200 μL. Cells were
counted in duplicate by flow cytometric analysis at a fixed
flow rate during a defined time period of 60 sec (counts
per minute; cpm). DC migration was expressed using the
following equation:
Cytokine secretion profile
The cytokine secretion profile of the different DC subsets
was assessed by a multiplex immunoassay (MIA). Briefly,
mature DCs were harvested, extensively washed and resus-
pended in fresh DC culture medium (5.0 × 105 cells/mL),
not containing any exogenous growth factor or cytokine.
After 24 hr of incubation, culture supernatants were ana-
lyzed for the presence of 11 different pro-inflammatory
and Th1/Th2-polarizing cytokines using a commercially
available MIA kit (FlowCytomix human Th1/Th2 11plex
kit, Bender Medsystems; Vienna, Austria), according to the
manufacturer's instructions.
IL-12p70 ELISA following CD40 ligation ("signal-3 assay")
Human CD40 ligand (CD40L)-expressing mouse 3T3
fibroblasts (kindly provided by Dr K. Thielemans, Free
University Brussels, Brussels, Belgium) were suspended in
a 48-well culture plate at a concentration of 2.5 × 105 cells
per well and incubated overnight at 37°C to allow stable
reattachment on the bottom surface of the well. The next
day, mature DCs were seeded on the 3T3 feeder cell layer
at a density of 5.0 × 105 cells per well in a total volume of
1 mL fresh DC culture medium. After 24 hr of co-incuba-
tion at 37°C, supernatants were carefully collected and
stored frozen at -20°C until further use. The production of
bioactive IL-12p70 was next determined using a commer-
cially available standard sandwich ELISA kit (eBioscience;
San Diego, CA, USA).
Autologous T cell stimulation capacity
To assess their autologous T cell stimulation capacity,
mature DCs were pulsed with a panel of 32 MHC class I-
restricted antigen epitopes derived from cytomegalovirus,
Epstein-Barr virus and influenza virus, designated to as
CEF peptide pool. The CEF peptide pool was obtained
through the NIH AIDS Research & Reference Reagent Pro-
gram (Division of AIDS, NIAID, NIH; Germantown, MD,
USA) and used at a total concentration of 1 μg/μL.
Peptide-pulsed DCs were subsequently co-incubated with
autologous PBLs at a 1:10 ratio in RPMI supplemented
with 1% human AB serum. By day 7 of coculture, PBLs
were harvested and restimulated with the CEF peptide
pool for an additional 6 hr. A peptide mixture composed
of human papilloma virus (HPV) type 16 E7 peptides
served as negative control. The HPV peptide pool con-
sisted of nine HPV16 E7 18- to 20-mer peptides (each over-
lapping by 10 amino acids), spanning the full length of
%[ (  migrated cells cpm cpm   =− − chemokine driven migration negativ ve control positive control    cpm )/ ] . ×100Journal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
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the HPV16 E7 protein (1 μg/μL; AC Scientific; Duluth, GA,
USA). Antigen-specific interferon (IFN)-γ secretion fol-
lowing peptide stimulation was determined by ELISA
(Peprotech; Rocky Hill, NJ, USA) as per the manufac-
turer's protocol.
For intracellular staining (ICS) of IFN-γ, PBLs (1 × 106)
were harvested after coculture with autologous CEF-
pulsed DCs and subjected to a similar antigen stimulation
protocol. Brefeldin A (1 μL; GolgiPlug™, BD Biosciences)
was added during the stimulation period in order to
sequester IFN-γ intracellularly. After 6 hr, PBLs were
washed with PBS containing 1% bovine serum albumin
and 0.1% sodium azide. Prior to the fixation and perme-
abilization procedure, cell surface staining for CD8 (PE,
clone SK1, BD Biosciences) and CD3 (PerCP, clone SK7;
BD Biosciences) was performed as described above. Next,
cells were fixated and permeabilized using BD FACS™ lys-
ing solution (1×) and permeabilizing solution 2 (1×).
Intracellular staining was performed using IFN-γ mAb (15
ng per 1 × 106 cells; FITC, clone B27, BD Biosciences).
Cells were subsequently incubated overnight at 4°C prior
to flow cytometric analysis.
mRNA electroporation of IL-15 DCs
DNA transcription templates encoding the enhanced
green fluorescent protein (eGFP) and influenza virus M1
matrix protein were respectively derived from the
pGEM4Z/EGFP/A64 (kindly provided by Dr. E. Gilboa,
then at Duke University Medical Center, Durham, NC,
USA) and pGEM4Z/M1/A64 (kindly provided by Dr. A.
Steinkasserer, University of Erlangen, Erlangen, Germany)
plasmid vectors, according to our previously described
protocol [9]. Subsequent in vitro transcription of mRNA
was performed using a commercially available T7
polymerase-based transcription kit (Ambion; Austin, TX,
USA), following the manufacturer's instructions.
Mature IL-15 DCs were harvested and washed twice in
serum-free IMDM culture medium (Cambrex Bio Science;
Verviers, Belgium) and Opti-MEM I medium (Gibco Inv-
itrogen), respectively. Next, 1 × 106 DCs were resuspended
in a total volume of 200 μL Opti-MEM I and transferred to
a 4.0-mm electroporation cuvette (Cell Projects; Harriet-
sham, UK). After addition of in vitro transcribed eGFP
mRNA (20 μg) or M1 mRNA (10 μg), electroporation was
performed using a Gene Pulser Xcell™ device (Bio-Rad
Laboratories; Hercules, CA, USA) at predefined settings
(300 V; 150 μF; 7.0 ms). The mRNA electroporation effi-
ciency was assessed by flow cytometric analysis of the
eGFP expression levels at different time points post-elec-
troporation (4 hr, 24 hr, 48 hr). Propidium iodide was
included in the assay to determine the post-electropora-
tion cell viability.
Antigen-presenting function of mRNA-electroporated IL-
15 DCs
HLA-A*0201+ IL-15 DCs were electroporated with M1-
encoding mRNA and cocultured at a 1:10 ratio with autol-
ogous PBLs in 24-well polystyrene culture plates. Six days
after initiation of the coculture experiments, PBLs were
harvested and counted using an automatic hemocytome-
ter.
To determine the presence of M1-specific CD8+ T lym-
phocytes, 1 × 106 PBLs were stained with anti-CD8 (FITC,
clone SK1; BD Biosciences) and PE-conjugated HLA-
A*0201 tetramer loaded with the influenza virus M1
matrix peptide (GILGFVFTL; kindly provided by Prof. P.
Van der Bruggen, Ludwig Institute for Cancer Research,
Brussels, Belgium). A dump channel (PerCP) was
included to enhance the specificity of the tetramer assay.
Concomitantly, a fraction of the cocultured PBLs was sub-
jected to antigen restimulation using two HLA-A*0201
restricted, virus-specific epitopes: the influenza matrix
protein M1 peptide (M158-66 [GILGFVFTL]; Eurogentec;
Seraing, Belgium) and an irrelevant peptide fragment
derived from carcinoembryonic antigen (CEA571-579
[YLSGANLNL]; Eurogentec). Both peptides were used at a
final concentration of 1 μg/mL. The duration of antigen
stimulation was 4 hours, after which the level of IFN-γ
producing CD8+ T cells was determined using a similar
ICS protocol as described above.
Data mining and statistical analysis
Flow cytometric data analysis was performed using
FlowJo version 8.4.4 (TreeStar; San Carlos, CA). Pheno-
typic results were expressed as Δ mean fluorescence inten-
sity (MFI), i.e.  the difference between the MFI values
obtained from the specific mAb and the corresponding
isotype-matched control, or calculated as a percentage of
positive cells using the SuperEnhanced D-max or Overton
histogram subtraction methods. GraphPad Prism 4.0 soft-
ware (GraphPad Software; San Diego, CA, USA) was used
for graphical data representations and statistical computa-
tions. Statistical analysis was performed using Student's t-
test or repeated-measures ANOVA with Bonferroni's post-
hoc testing, where appropriate. Any P-value < 0.05 was
considered statistically significant.
Results
Immature IL-15 DCs display a unique phenotype
Immature monocyte-derived DCs differentiated for 2 days
in the presence of GM-CSF and IL-15 were evaluated for
the phenotypic expression of CD1a, CD14, CD56, CD80,
CD207 (Langerin) and CD209 (DC-SIGN) (Figure 1). The
monocyte marker CD14 was found to be rapidly down-
regulated on immature IL-15 DCs, although a persistent
basal expression level could still be observed (Figure 1a).Journal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
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This finding contrasts with the near-absence of CD14 on
conventional immature IL-4 DCs (Figure 1b). The incom-
plete disappearance of CD14 on the cell surface of IL-15
DCs could not be explained by the short-term duration of
culture (2 days), since long-term cultured IL-15 DCs (6
days) displayed even higher levels of CD14 (data not
shown). As opposed to CD14, the cell surface expression
of DC-related molecules CD1a and CD209 (DC-SIGN)
was found to be more pronounced on IL-4 DCs. Con-
versely, IL-15 DCs expressed the costimulatory molecule
CD80 at the immature stage whereas IL-4 DCs did not. In
addition, IL-15 DCs showed a unique phenotype with
partial positivity for CD207, a LC-related surface antigen,
and CD56, a marker with a dominant expression on NK
cells.
TLR7/8-activated IL-15 DCs acquire a mature phenotype
We first assessed the phenotypic differences between
mature IL-15 DCs (Figure 2a and 2b) and "standard"
mature IL-4 DCs (Figure 2c). As shown in figure 2, matu-
ration of IL-15 DCs and IL-4 DCs was associated with an
upregulation of CD40, CD80, CD86 and of the DC matu-
ration marker CD83. The most striking difference between
IL-15 DCs and conventionally matured IL-4 DCs was the
higher level of CD83 expression in the latter DC subset,
consistent with a more mature phenotype (Figure 2; Addi-
tional File 1).
Divergent phenotypic results were obtained with the 2
protocols used for the induction of IL-15 DC maturation:
(i) a classic combination of pro-inflammatory cytokines
(cc-mDC) versus (ii) a TLR7/8 ligand-containing matura-
tion cocktail (TLR-mDC). As shown in Figure 2, the cos-
timulatory molecules CD70, CD80 and CD86 were
expressed at consistently higher levels upon activation of
IL-15 DCs with the TLR7/8 agonist-based cocktail (TLR-
mDC) as opposed to the conventional cytokine cocktail
(cc-mDC). Moreover, a more profound maturation state
was reached in TLR7/8-matured IL-15 DCs. This was
reflected by the increased surface expression of CD83. The
Phenotypic characteristics of immature IL-15 DCs Figure 1
Phenotypic characteristics of immature IL-15 DCs. Immature DCs were analyzed by flow cytometry for the expression 
of CD1a, CD14, CD56, CD80, CD207 (Langerin) and CD209 (DC-SIGN). The histograms represent the expression of the 
indicated cell surface antigens (bold-line histograms) and the corresponding isotype controls (grey-filled histograms). The mean 
± SEM percentage of positive cells (%) and delta MFI ± SEM (ΔMFI) were calculated as specified in the "Methods" section (n = 
3-6). (a) Phenotype of monocyte-derived DCs generated in the presence of GM-CSF + IL-15 and harvested at the immature 
stage 2-3 days after initiation of the DC culture. (b) Corresponding phenotypic profile of conventional immature DCs, differ-
entiated in the presence of GM-CSF + IL-4.Journal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
Page 7 of 16
(page number not for citation purposes)
low expression of costimulatory molecules and CD83
after maturation of IL-15 DCs with the cytokine cocktail
(cc-mDC) sharply contrasted with the effects of this mat-
uration cocktail on IL-4 DCs (Figure 2; Additional file 1).
We next examined the effect of culture duration on the
phenotype of mature IL-15 DCs. No apparent differences
were observed between short-term (Figure 2a) and long-
term cultured IL-15 DCs (Figure 2b), with the exception of
CD86 which was found to be more pronounced in short-
term cultured IL-15 DCs. The cell surface expression level
of CD83 was independent of the duration of DC culture,
suggesting that an equal maturation level can be obtained
after short-term culture of IL-15 DCs.
A detailed overview of the phenotypic characteristics of
mature IL-15 DCs is provided in "Additional File 1".
Immature IL-15 DCs are capable of phagocytosis
Immature IL-15 DCs were examined for their intrinsic
phagocytosis capacity using a FITC-dextran endocytosis
assay. Both short-term and long-term cultured IL-15 DCs
showed a high potential for FITC-dextran phagocytosis, as
reflected by the average number of dextran+ cells and the
mean fluorescence intensity of the FITC signal (Figure 3).
The 1-hr FITC-dextran uptake did not differ significantly
between both IL-15 DC subsets, and was found to be com-
parable to that of immature IL-4 DCs. Mature DCs dis-
played a reduced phagocytosis capacity compared to their
immature counterparts (data not shown).
Migratory potential of IL-15 DCs
The migratory properties of immature IL-15 DCs (iDC),
conventionally matured IL-15 DCs (cc-mDC) and TLR7/
8-matured IL-15 DCs (TLR-mDC) were compared by
assessment of their CCR7 expression pattern and their in
vitro  migratory potential using a standard Transwell™
chemotaxis assay.
The phenotypic analysis revealed near-absent expression
of CCR7 in immature IL-15 DCs, both after short-term
(Figure 4a) and long-term DC culture (Figure 4b). Conse-
quently, immature IL-15 DCs were unable to migrate to
the secondary lymph node chemokine CCL21 in a Tran-
swell™ chemotaxis assay (Figure 4c). Dendritic cells
matured with the conventional mixture of pro-inflamma-
tory cytokines (cc-mDC) displayed only weak CCR7 posi-
tivity. In line with their low CCR7 surface expression, we
Phenotypic characteristics of mature IL-15 DCs Figure 2
Phenotypic characteristics of mature IL-15 DCs. Immunophenotypic expression of CD40, CD70, CD80, CD83, CD86 
and CD209 (DC-SIGN) by (a) short-term cultured IL-15 DCs, (b) long-term cultured IL-15 DCs and (c) conventional IL-4 
DCs after maturation induction with either a classic maturation cocktail (cc-mDC; dashed-line histograms) or a TLR7/8 ligand-
containing mixture (TLR-mDC; bold-line histograms). Isotype controls are represented by the grey-filled histograms. A 
detailed overview of the flow cytometry data of mature DCs is provided in "Additional file 1" (n = 4).Journal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
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observed no relevant CCR7-driven migration by short-
term and long-term conventionally matured IL-15 DCs
(Figure 4c). Conversely, a marked up-regulation of the
CCR7 cell surface expression was noted upon maturation
of IL-15 DCs with the TLR7/8 agonist-based cocktail (TLR-
mDC). Accordingly, TLR7/8-matured IL-15 DCs were
endowed with potent migratory activity in the chemotaxis
assay. The increased CCR7 expression state in long-term
cultured TLR7/8-matured IL-15 DCs was not associated
with a better migratory response as compared to the short-
term cultured counterparts. As shown in figure 4c, a supe-
rior chemotactic potential was observed in short-term cul-
tured TLR7/8-matured IL-15 DCs; their in vitro migratory
behaviour was virtually comparable to that of standard IL-
4 DCs (Figure 4c; IL-4 cc-mDC vs. short-term IL-15 TLR-
mDC: P = 0.62).
Cytokine secretion profile of IL-15 DCs
The MIA technique was used to assess the 24-hr cytokine
secretion profile of mature IL-15 DCs and IL-4 DCs. As
indicated in Table 2, the expression of a panel of 11 Th1/
Th2-polarizing and pro-inflammatory cytokines was ana-
lyzed. Maturation of IL-15 DCs was induced using two dif-
ferent protocols, as described above (cc-mDC and TLR-
mDC).
As shown in table 2, neither IL-15 DCs nor IL-4 DCs were
capable of primary IL-12p70 production. Since DC-medi-
ated release of IL-12p70 upon CD40-CD40L signalling is
considered to be more important than its primary produc-
tion, we performed coculture experiments with DCs and
CD40L-expressing 3T3 mouse fibroblast cells to mimic
the in vivo CD40-CD40L molecular interaction between
DCs and T-lymphocytes ("signal-3 assay"). As depicted in
figure 5, no bioactive IL-12p70 could be detected in the
coculture supernatants of conventionally matured IL-4
and IL-15 DCs (cc-mDC). By contrast, IL-15 DCs were
capable of secreting detectable amounts of IL-12p70 upon
TLR7/8 triggering (TLR-mDC). A more prominent, albeit
heterogeneous, increment in IL-12p70 production was
found after long-term culture of TLR7/8-matured IL-15
DCs (Figure 5). In addition, we observed that the primary
culture supernatants of TLR7/8-matured IL-15 DCs con-
tained high levels of IFN-γ, as opposed to conventionally
matured IL-4 and IL-15 DCs. The IFN-γ secretion by TLR7/
8-matured IL-15 DCs was independent of the duration of
culture (Table 2; IFN-γ short-term vs. long-term TLR-mDC:
P = 0.17).
The cytokine profile of IL-15 DCs was further explored by
analyzing the release of Th2-related cytokines. As shown
in table 2, no relevant amounts of IL-4, IL-5 and IL-10
could be detected in the culture supernatants of IL-15 DCs
and IL-4 DCs (Table 2).
Moreover, signalling through TLR7/8 (TLR-mDC)
resulted in the induction of high levels of TNF-α and IL-6
(Table 2). The production of the latter cytokine was sub-
stantially more pronounced in TLR-mDC as compared to
cc-mDC. No statistically significant differences were
found between short-term and long-term cultured TLR7/
8-activated IL-15 DCs regarding their capacity to produce
pro-inflammatory cytokines.
Efficient induction of viral antigen-specific CD8+ T cell 
responses by IL-15 DCs
In order to determine their capacity to present viral anti-
gens and to elicit antigen-specific CD8+ T cell responses,
mature DCs were pulsed with a peptide pool covering a
panel of 32 MHC-I restricted T cell epitopes derived from
the human cytomegalovirus, Epstein-Barr virus and influ-
enza A virus (CEF), after which they were cocultured with
autologous PBLs for 7 days. For all DC subsets tested,
enhanced antigen-specific CD8+  T cell responses were
observed after antigen rechallenge with the CEF peptide
pool as compared to an irrelevant peptide pool contain-
ing HPV16 E7 peptide sequences, which was included to
evaluate the non-specific IFN-γ production (Figure 6).
Mannose receptor-mediated endocytosis of FITC-dextran  particles Figure 3
Mannose receptor-mediated endocytosis of FITC-
dextran particles. Histogram overlays depicting the in vitro 
uptake of FITC-dextran molecules by immature DCs, respec-
tively short-term cultured IL-15 DCs (left), long-term cul-
tured IL-15 DCs (middle) and control IL-4 DCs (right). The 
FITC-dextran endocytosis at 37°C (bold-line histograms) is 
compared to the non-specific fluorescence at 4°C (dashed-
line histograms) and to the autofluorescence from unlabeled 
samples (grey-filled histograms), as described in "Methods". 
The uptake of FITC-dextran was quantified as mean ± SEM 
percentage of FITC-dextran positive cells (%) and as delta 
MFI ± SEM (ΔMFI), which was calculated by subtracting the 
MFI value of the non-specific FITC-dextran uptake at 4°C 
from the MFI value obtained at 37°C (n = 3).Journal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
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We first examined whether the type of DC maturation
cocktail (cc-mDC vs. TLR-mDC) had an impact on the
capacity of IL-15 DCs to stimulate viral antigen-specific T
cells. As shown in figure 6, a potent induction of antigen-
specific CD8+ T cell responses was observed when IL-15
DCs were exposed to the TLR7/8 ligand-based maturation
cocktail (TLR-mDC). By contrast, restimulation of PBLs
after prior coculture with conventionally matured IL-15
DCs (cc-mDC) resulted in much lower levels of secreted
IFN-γ, as determined by ELISA (Figure 6a; short-term TLR-
mDC vs. cc-mDC, P < 0.001; long-term TLR-mDC vs. cc-
mDC, P = 0.004). This trend was also reflected by our ICS
experiments, although the difference in number of IFN-γ+
CD8+ T cells between both maturation cocktails did not
reach statistiscal significance (Figure 6b; short-term TLR-
mDC vs. cc-mDC, P = 0.07; long-term TLR-mDC vs. cc-
mDC, P = 0.06).
We next determined the effect of culture duration on the
induction of antigen-specific CD8+ T cell responses by IL-
15 DCs. Short-term IL-15 DCs showed a distinctive supe-
riority over their long-term cultured counterparts, regard-
less of the maturation cocktail used. This was evidenced
by the increased ability of PBLs, stimulated by short-term
cultured CEF-pulsed IL-15 DCs, to secrete IFN-γ upon
antigen rechallenge. As shown in figure 6a, the antigen-
specific IFN-γ release after CEF-restimulation of PBLs, was
markedly increased in the short-term IL-15 DC subset.
This phenomenon was found to be irrespective of the
maturation protocol used (Figure 6a; short-term vs. long-
term cc-mDC, P  = 0.01; short-term vs.  long-term TLR-
mDC, P = 0.006). A parallel trend was observed in the
number of IFN-γ+ CD8+ T cells (Figure 6b).
In general, a potent ability to induce recall immune
responses could be attributed to short-term TLR7/8-
CCR7 expression and migratory capacity Figure 4
CCR7 expression and migratory capacity. Histogram overlays comparing the CCR7 expression on (a) short-term cul-
tured and (b) long-term cultured IL-15 DCs, either at the immature stage (iDC) or at the mature stage (cc-mDC: + TNF-α, 
IL1β, IL-6 and PGE2 for the last 24 hours; TLR-mDC: + R-848, IFN-γ, TNF-α and PGE2 for the last 24 hours). Bold-line histo-
grams represent the CCR7-specific staining, whereas the corresponding isotype controls are indicated by grey-filled histograms 
(n = 3). (c) Migration of the indicated DC subsets towards CCL21 in a Transwell chemotaxis assay. The mean ± SEM percent-
ages of migrated cells after 180 min were calculated according to the formula specified in "Methods" (n = 3-6; *, P = 0.01). The 
values shown in the grey bars represent the cell viabilities of the different DC subsets (mean ± SEM; n = 3-6).Journal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
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matured IL-15 DCs. The superior T cell stimulation capac-
ity of this DC subset was next verified against standard
mature IL-4 DCs, and confirmed by the enhanced antigen-
specific IFN-γ release and the higher frequencies of IFN-γ+
CD8+ T cells (Figure 6).
mRNA electroporation is an effective strategy for antigen 
loading of IL-15 DCs
In view of the capacity of short-term TLR7/8-matured IL-
15 DCs to mount cogent antigen-specific T cell responses
after passive pulsing of antigen peptides, we next assessed
whether mRNA electroporation could serve as an alterna-
tive antigen loading strategy of this DC subset. As a 'proof-
of-principle' experiment for their mRNA transfectability,
short-term TLR7/8-matured IL-15 DCs were electropo-
rated in the presence or absence of eGFP mRNA. The
mRNA electroporation efficiency was assessed by flow
cytometry, showing stable transgene eGFP expression at
different time points post-electroporation (4 hr, 24 hr, 48
hr). Percentages of eGFP+ cells and their respective fluores-
cence intensities are shown in Figure 7. Besides the high
transfection efficiency, electrotransfection of IL-15 DCs
had no major impact on cell viabilities measured 4 hr, 24
hr and 48 hr after mRNA electroporation. Cell viability
data are presented in figure 7 (Figure 7).
After the initial demonstration of their mRNA trans-
fectability, we subsequently determined whether IL-15
DCs were able to elicit an antigen-specific cellular
immune response after electroporation of antigen-encod-
ing mRNA. For this purpose, PBLs from HLA-A*0201+
healthy blood donors were exposed to autologous short-
term cultured mature IL-15 DCs (TLR-mDC), that were
electroporated as described above with mRNA encoding
the influenza virus matrix protein M1. After one week of
coculture, expansion of M1(GILGFVFTL)  tetramer-positive
CD8+ T cells could be demonstrated in 3 out of 4 donors
(Figure 8a). To confirm the findings of the tetramer stain-
ing, PBLs were restimulated with the HLA-A*0201-
restricted peptides M1 (positive control) and CEA (nega-
tive control). After 4 hr of selective antigen rechallenge
(M1), IFN-γ+ CD8+ T cells could be observed as shown in
Figure 8b. Stimulation with the irrelevant CEA peptide
confirmed the antigen specificity of the observed immune
responses (Figure 8b; M1 vs. CEA, P = 0.03).
Discussion
The current standard to generate DCs for use in clinical tri-
als consists of a one-week, two-step culture protocol in
which monocyte-derived DCs are first differentiated in the
presence of GM-CSF and IL-4, and subsequently matured
with a combination of pro-inflammatory cytokines
[8,34]. In the present study, we established a novel proto-
col for the generation of monocyte-derived DCs by imple-
menting the following modifications: (1)  short-term
culture for 2-3 days instead of 7 days, (2) alternative dif-
ferentiation in the presence of GM-CSF and IL-15 (IL-15
DCs) and (3) alternative maturation induction through
engagement of the TLR7/8 signalling pathway.
The modified protocol described here proved feasible for
rapidly generating stimulatory and migratory DCs with-
Table 2: Cytokine secretion profile of mature DCs.
short-term IL-15 DCs long-term IL-15 DCs IL-4 DCs
cc-mDC TLR-mDC cc-mDC TLR-mDC cc-mDC
(pg/mL) (pg/mL) (pg/mL) (pg/mL) (pg/mL)
Typical Th1-polarizing
IL-12p70 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
IFN- 0 ± 0 3671 ± 394 0 ± 0 4510 ± 686 0 ± 0
IL-2 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Typical Th2-polarizing
IL-4 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
IL-5 9 ± 5 6 ± 6 0 ± 0 0 ± 0 11 ± 6
IL-10 0 ± 0 4 ± 4 0 ± 0 50 ± 50 0 ± 0
Pro-inflammatory
TNF- 281 ± 124 1132 ± 551 1078 ± 268 4424 ± 1446 39 ± 16
TNF- 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
IL-1 60 ± 55 0 ± 0 146 ± 64 55 ± 33 71 ± 45
IL-6 1065 ± 102 8163 ± 3246 1660 ± 78 13391 ± 2732 793 ± 51
IL-8 9914 ± 986 6109 ± 2468 3876 ± 483 2061 ± 109 9495 ± 2289
Abbreviations used: short-term: 3-day culture; long-term: 7-day culture; cc-mDC: conventional maturation cocktail (TNF-α, IL1β, IL-6 and PGE2); 
TLR-mDC: TLR7/8 agonist-based maturation cocktail (R-848, IFN-γ, TNF-α and PGE2). Results are expressed as mean ± SEM (pg/mL).Journal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
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out any detrimental effects on cell viability and function.
Neither differentiation with IL-15 nor TLR7/8 triggering
had a negative influence on cell viability (data not
shown). IL-15 DCs displayed a typical DC morphology
already after 2-3 days of in vitro culture. As compared to
standard IL-4 DCs, however, we observed that IL-15 DCs
still retained some CD14 on their cell surface which,
together with the lower expression levels of CD1a and
CD209 (DC-SIGN), points to a less differentiated DC
phenotype. This observation seemed unrelated to the
duration of IL-15 DC culture, since long-term cultured IL-
15 DCs expressed even higher levels of CD14 as compared
to their short-term cultured counterparts. Previous studies
have shown that replacement of IL-4 by IL-15 switches the
differentiation of monocytes from 'genuine' monocyte-
derived DCs to cells with a complex LC-like phenotype
[22,23,40,41]. This finding has fuelled the interest in
alternative differentiation of monocyte-derived DCs by IL-
15, since LC-like DCs have been advocated as ideal cellu-
lar vaccine vehicles in view of their potent antigen-pre-
senting capacity [4,42]. In the present study, we
confirmed the Langerin (CD207)-positivity of IL-15 DCs
[22,23] and showed that CD207 upregulation is already
maximal after short-term culture.
Another intriguing phenotypic finding was that a fraction
of IL-15 DCs expresses CD56, a marker with predominant
expression on natural killer (NK) and NK-T cells [43]. In
this regard, IL-15 DCs bear phenotypic similarity with
monocyte-derived DCs generated in the presence of GM-
CSF and IFN-γ (IFN-DCs). A subset of IFN-DCs was
recently identified as being CD56-positive and endowed
with endogenous cytotoxic activity, mediated by TNF-α-
related apoptosis-inducing ligand (TRAIL) [43-45]. It is
not completely speculative to draw a parallel between
these IFN-DCs and IL-15 DCs, since there is evidence that
type I interferons regulate IL-15 expression, suggesting a
close relationship between both cytokines. In view of
these data, it might be of particular interest to further elab-
orate on the phenotypic and potential functional resem-
blance of IFN-DCs and IL-15 DCs.
While it induces full phenotypic maturation in conven-
tional IL-4 DCs, we observed that IL-15 DCs exhibit a sub-
optimal phenotype upon maturation induction with the
widely adopted pro-inflammatory cytokine cocktail (cc-
mDC). This was exemplified by the lower expression lev-
els of the DC maturation marker CD83 and of vital cos-
timulatory molecules such as CD80 and CD86. These
phenotypic differences indicate that the results obtained
with the classic maturation cocktail in IL-4 DCs cannot
necessarily be extrapolated to IL-15 DCs.
Upon TLR activation, however, IL-15 DCs undergo an effi-
cient maturation program and reach acceptable levels of
CD83, CD70, CD80 and CD86; their phenotype appears
close to that of fully mature IL-4 DCs, despite a distinct
expression of CD83. The functional relevance of CD70
expression on the cell surface of TLR7/8-matured IL-15
DCs should be stressed, since CD70+ DCs favour Th1
immunity via the CD70-CD27 signalling pathway in an
IL-12p70-independent fashion [46].
We next examined several functional endpoints to which
IL-15 DCs must conform in order to be a valid immuno-
therapeutic vaccine candidate. Migration of DCs to sec-
ondary lymphoid organs is generally considered a conditio
sine qua non for the success of DC-based immunotherapy
[47]. The migratory potential of IL-15 DCs has been
sparsely investigated until present, with only one prior
IL-12p70 production following CD40 ligation ("signal-3  assay") Figure 5
IL-12p70 production following CD40 ligation ("signal-
3 assay"). Dendritic cells were differentiated in the pres-
ence of GM-CSF + IL-4 for 6 days (control IL-4 DCs), or in 
the presence of GM-CSF + IL-15 for 2 days (short-term IL-15 
DCs) or 6 days (long-term IL-15 DCs). Dendritic cell matu-
ration was induced by addition of two different maturation 
cocktails 24 hr prior to DC harvest (cc-mDC: TNF-α, IL1β, 
IL-6 and PGE2; TLR-mDC: R-848, IFN-γ, TNF-α and PGE2). 
Production of the Th1-polarizing cytokine IL-12p70 was 
assessed by ELISA after a 24-hr coculture of mDCs and 
CD40L-expressing 3T3 fibroblasts, as specified in "Methods". 
Results are shown from 3-9 independent experiments, each 
symbol expressing the mean of triplicate ELISA values 
obtained from one individual donor. The horizontal bars rep-
resent the mean IL-12p70 production in pg/mL per condition 
(*, P = 0.02).Journal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
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report demonstrating their migratory responsiveness to
the CCR6 ligand CCL20 [22]. However, acquisition of
CCR7 upon maturation is one of the critical factors
involved in effective DC migration to the draining lymph
nodes [6,48,49].
As expected, immature DCs showed absent expression of
CCR7 and correspondingly failed to migrate in the direc-
tion of CCL21 in a standard Transwell™ migration assay,
hence validating our experimental set-up [48]. While the
classical combination of pro-inflammatory cytokines
induces a migratory phenotype in standard IL-4 DCs (this
study and [36,50]), IL-15 DCs are found to be refractory
to this maturation cocktail. The low CCR7 expression and
concomitant weak migratory potential of conventionally
matured IL-15 DCs could be, at least in part, explained by
their less mature phenotype, as reflected by the relative
low expression of CD83. In contrast, TLR7/8 agonist-
matured IL-15 DCs are capable of effective CCR7-medi-
ated migration. This result is in line with recent studies,
showing that the addition of PGE2 to the maturation pro-
tocol reinstates the migratory program affected by TLR sig-
nalling [32,33]. Our results clearly point to a superior
migratory potential of short-term cultured TLR7/8-acti-
vated IL-15 DCs, which combine CCR7 expression with a
migratory activity close to that of standard mature IL-4
DCs.
Besides possessing strong migratory properties, produc-
tion of Th1-polarizing and pro-inflammatory cytokines is
considered to be another characteristic of immunostimu-
latory DCs. Dendritic cell-mediated production of IL-
12p70 upon T cell encounter in the lymph nodes is
regarded as a decision step in the induction of a desired
Th1 immune response [10]. Absent IL-12p70 release is a
major barrier to effective immunotherapy, which could be
circumvented by modifying the current in vitro DC matu-
ration protocol [32,51]. As mentioned previously, the
combination of TNF-α, IL-1β, IL-6 and PGE2 has been
implemented as the standard maturation cocktail in most
DC vaccine trials, despite its well-known drawback of
hampering IL-12p70 production [38,39]. Analogous to
conventional IL-4 DCs, we observed no overt IL-12p70
release by IL-15 DCs matured with the pro-inflammatory
cytokine cocktail. Conversely, TLR7/8-activated IL-15 DCs
are able to produce detectable amounts of IL-12p70 after
mimicking in vivo T cell encounter with CD40L-expressing
fibroblasts. It should be noted that typical high IL-12p70
levels could not be attained after activation of the TLR7/8
pathway in IL-15 DCs. This may be due to an intrinsic ina-
bility of IL-15 DCs to produce IL-12, as had been previ-
ously suggested [23]. The inclusion of PGE2  in our
maturation cocktail provides another possible explana-
tion. In contrast to recent studies [32,33], we found that
exposure to PGE2clearly suppresses the IL-12p70 release
Induction of viral antigen-specific CD8+ T cell responses Figure 6
Induction of viral antigen-specific CD8+ T cell responses. As described previously, short-term and long-term cultured 
IL-15 DCs were matured using two different maturation cocktails (cc-mDC: TNF-α, IL1β, IL-6 and PGE2; TLR-mDC: R-848, IFN-
γ, TNF-α and PGE2). Conventionally matured IL-4 DCs were used as a control (control IL-4 DCs). The mDCs were harvested, 
pulsed with a pool of cytomegalovirus-, Epstein-Barr virus- and influenza a virus (CEF)-derived peptides, and cocultured with 
autologous PBLs for 7 days. Viral antigen-specific CD8+ T cell responses were determined after this 7-day period and a short 
restimulation with the CEF peptide pool (CEF; filled bars). As specified in "Methods", the antigen-specific production of IFN-γ 
was assessed using two techniques: (a) ELISA to detect the amount of IFN-γ produced after restimulation (pg/mL) and (b) ICS 
to determine the % of IFN-γ+ CD8+ T cells. The non-specific IFN-γ release in response to restimulation with an irrelevant HPV 
peptide pool is shown (HPV; unfilled bars). Results are expressed as mean ± SEM of three independent experiments (*, P = 
0.03; **, P = 0.006; ***, P < 0.001).Journal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
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by TLR7/8-matured IL-15 DCs (data not shown). How-
ever, the physiological relevance of this limited IL-12p70
production capacity is questionable for several reasons.
First and foremost, it has been suggested that even minor
amounts of IL-12p70 have a Th1-skewing influence on the
immune response [52,53]. Thus one can hypothesize that
the qualitative aspects (presence or absence of IL-12p70)
are far more important than the quantitative. Within this
context, it is also difficult to judge the significance of the
more pronounced IL-12p70 release by long-term cultured
TLR7/8-matured IL-15 DCs as opposed to their short-term
counterparts. Secondly, IL-12p70 is an important but not
exclusive signal for the induction of Th1 responses. Effec-
tive cellular immune responses can occur in the absence
of functional IL-12p70, as has been exemplified in the
case of Langerhans cells [42]. Thirdly, we were able to
show that TLR7/8-activated IL-15 DC preparations con-
tain high amounts of IFN-γ, which are likely derived from
expanded NK cells in the IL-15 DC cultures [25]. A recent
study by Hardy et al. has pointed out the pivotal role of
contaminating IFN-γ producing NK cells in the induction
of Th1 immunity by IL-15 DCs. As such, it might be spec-
ulated that NK cell-derived IFN-γ can partially replace IL-
12p70 as a Th1-polarizing cytokine, thereby providing
another mechanism by which IL-15 DCs can induce cellu-
lar immunity in an IL-12-independent fashion [25].
Fourthly, TLR7/8-matured IL-15 DCs express CD70,
which contributes to IL-12-independent Th1 differentia-
tion as described above [46]. Lastly, Dubsky et al. have
recently elucidated that the enhanced potential of IL-15
DCs to induce cellular immune responses can be ascribed
mRNA transfectability of mature IL-15 DCs Figure 7
mRNA transfectability of mature IL-15 DCs. Mono-
cytes were cultured for 2 days with GM-CSF + IL-15, fol-
lowed by a 24-hr incubation with a TLR7/8 agonist-based 
maturation cocktail (TLR-mDC). The resultant mDCs were 
harvested and electroporated with mRNA encoding the 
enhanced green fluorescent protein (eGFP). The green dots 
represent the mean ± SEM percentages of eGFP+ cells, as 
assessed by flow cytometry at different time points post-
electroporation (4 hr, 24 hr, 48 hr). The insert shows a rep-
resentative histogram overlay in which the flow cytometric 
eGFP expression 4 hr post-electroporation (green line histo-
gram) is compared with the expression in a mock-electropo-
rated negative control (grey-filled histogram). The values 
below indicate the delta MFI ± SEM of the eGFP expression 
(ΔMFI) and the mean ± SEM percentage of viable cells (%) at 
4 hr, 24 hr and 48 hr following mRNA electrotransfection of 
IL-15 DCs (n = 5).
Induction of antigen-specific CD8+ T cell responses by  mRNA-electroporated mature IL-15 DCs Figure 8
Induction of antigen-specific CD8+ T cell responses by 
mRNA-electroporated mature IL-15 DCs. Short-term 
cultured IL-15 DCs were matured with our TLR7/8 agonist-
based maturation cocktail (TLR-mDC), electroporated with 
mRNA encoding the influenza virus matrix protein M1 and 
cocultured with autologous PBLs for 6 days. (a) The expan-
sion of M1-tetramer binding CD8+ T cells was determined by 
flow cytometry. The lower dot plot represents the observed 
percentage of M1-tetramer+ CD8+ T cells in one representa-
tive donor (n = 4; mean ± SEM percentage of M1-tetramer+ 
CD8+ T cells: 4.4 ± 2.9). Correct positioning of the M1-
tetramer+ CD8+ gate was defined by the respective negative 
control, as exemplified in the upper dot plot. (b) Simultane-
ously, a fraction of the PBL was harvested and stimulated 
with an irrelevant HLA-A*0201-restricted peptide (CEA) or 
rechallenged with the immunodominant influenza matrix pro-
tein (M1). The mean ± SEM percentage of antigen-specific 
IFN-γ+ CD8+ T cells was determined by ICS, as specified in 
the "Methods" section (n = 4; *, P = 0.03).Journal of Translational Medicine 2009, 7:109 http://www.translational-medicine.com/content/7/1/109
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in part to membrane transpresentation of the Th1-polariz-
ing cytokine IL-15 [24].
Efficient antigen presentation is another prerequisite that
DCs must fulfill in order to be considered for implemen-
tation in DC-based immunotherapy protocols. Previous
studies convincingly showed that IL-15 DCs are highly
capable of inducing antigen-specific T cell responses in
both viral and tumor antigen models [22,24,41]. It has
been put forward that IL-15 DCs have an optimal antigen-
presenting capacity; a recent study by Dubsky et al. has
emphasized their potent ability to prime and expand
high-avidity tumor antigen-specific CD8+ cytotoxic T lym-
phocytes [24]. Our study extend these findings in several
important respects. In the first place, activation of IL-15
DCs with a TLR7/8 stimulus appears to result in enhanced
antigen-specific T cell responsiveness compared to matu-
ration with a standard combination of pro-inflammatory
cytokines. This observation should be interpreted together
with the other effects of the two studied maturation cock-
tails on IL-15 DCs. On the basis of their phenotypic pro-
file and their impaired ability for CCR7-driven migration
and cytokine production, it can be hypothesized that IL-
15 DCs are relatively inert to classical maturation stimuli,
thereby providing an explanation for their inferior capac-
ity to induce antigen-specific T cell responses. Since fully
mature, immunostimulatory DCs are required for success-
ful cancer immunotherapy, the clinical use of cytokine
cocktail-matured IL-15 DCs cannot be recommended.
Conversely, TLR7/8-matured IL-15 DCs showed a strong T
cell stimulation capacity. This is particularly true for short-
term cultured IL-15 DCs, which demonstrated a clear
superiority over their long-term cultured counterparts and
over conventional IL-4 DCs with regard to the induction
of antigen-specific CD8+ T cell responses.
Taken together, short-term cultured and TLR7/8-matured
IL-15 DCs best meet the imposed requirements to be rec-
ognized as immunostimulatory DCs. Not only do they
possess an accurate phenotype as described above, they
also combine strong migratory properties with some
degree of IL-12p70 production and, most importantly,
with a potent ability to promote antigen-specific T cell
responses. Despite a more pronounced secondary produc-
tion of IL-12p70, their long-term cultured counterparts
behaved inferior with respect to migration and T cell stim-
ulation capacity. In addition, reducing the time of DC cul-
ture facilitates the still arduous and costly process of ex
vivo DC generation. Since short-term culture and TLR7/8-
induced maturation of IL-15 DCs was considered as the
"best-fit" approach to generate immunostimulatory DCs,
the last part of our study was dedicated to the mRNA elec-
troporability of this DC subset. Electroporation of mRNA
is being increasingly applied in clinical vaccination trials
as an elegant strategy for antigen loading of DCs [54,55].
The attractiveness of this technique is based on the fact
that it overcomes several drawbacks of other antigen
delivery methods, such as the biosafety issues posed by
viral gene delivery or the need for genome integration and
the related risk of insertional mutagenesis associated with
DNA transfection. In contrast to exogenous peptide puls-
ing, mRNA electroporation does not require prior knowl-
edge of the HLA restriction characteristics of the antigen
epitopes nor the need for HLA-matched donor DCs [55-
57]. Here we demonstrate for the first time the mRNA
transfectability of IL-15 DCs. Short-term cultured TLR7/8-
matured IL-15 DCs show accurate transgene expression
after eGFP mRNA electroporation, consistent with prior
studies on TLR7/8-mediated DC maturation [31,58].
Moreover, the observation that M1 mRNA-electroporated
IL-15 DCs are capable to induce influenza matrix protein
M1-specific T cells further proves the feasibility and appli-
cability of this method.
Conclusions
In conclusion, we propose a novel approach for the gen-
eration of DCs, based on a combined strategy of (1) short-
term culture of monocyte-derived DCs, (2) differentiation
in the presence of IL-15 and (3) maturation using a TLR7/
8 ligand-based cocktail. This integrative approach results
in the generation of DCs that meet the phenotypic and
functional endpoints for implementation in clinical vacci-
nation trials.
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